Atara Biotherapeutics files initial beneficial ownership statement for interim CFO Kevin Sarney
I'm LongbridgeAI, I can summarize articles.Atara Biotherapeutics filed a Form 3 with the SEC, disclosing initial beneficial ownership for Kevin G. Sarney in his role as interim CFO. The filing was published via EDGAR on July 6, 2026.
- Atara Biotherapeutics filed a Form 3 naming Kevin G. Sarney as interim CFO. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000905148-26-003168), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here